INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE & SHARE ANALYSIS - GROWTH TRENDS & FORECASTS (2023 - 2028)
Intravenous Immunoglobulin Market Analysis:
The intravenous immunoglobulin market is projected to experience a compound annual growth rate (CAGR) of 7.13% during the forecast period of 2022–2027.
The COVID-19 pandemic, particularly in its later stages, is anticipated to have a positive impact on the growth of the intravenous immunoglobulin market. A study titled “COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience,” published in December 2020, revealed that 70% of individuals with primary immunodeficiency (PID), symptomatic secondary immunodeficiency (SID), autoinflammatory diseases, and C1 inhibitor deficiency were infected with the SARS-CoV-2 virus. Out of these individuals, 59% were admitted to hospitals, with 8% requiring intensive care. This highlights the increased vulnerability of immune-deficient individuals to COVID-19, thereby driving the demand for intravenous immunoglobulin therapies during the pandemic. Furthermore, a published article in October 2020 titled “The use of Intravenous Immunoglobulin Gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial” suggested that the administration of intravenous immunoglobulin in patients with severe COVID-19 infection could improve clinical outcomes and significantly reduce mortality rates associated with SARS-CoV-2 viral infection. Consequently, the market is expected to experience robust growth during the pandemic due to these factors.
Moreover, the market’s growth is further propelled by significant factors such as the increasing elderly population, greater adoption of immunoglobulin treatment, and the rising prevalence of immunodeficiency diseases and bleeding disorders.
Get the free sample report of the Intravenous Immunoglobulin Market
Comments
Post a Comment